Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07600762 · ClinicalTrials.gov registry record · Phase 1
A Study to Assess Adverse Events, Tolerability and How a Single Oral Dose of Nacresertib Moves Through the Body In Healthy Adult Japanese Participants
A Phase 1 study, sponsored by AbbVie.
- Not yet
- Registry status
- Phase 1
- Development phase
- 12
- Enrollment target
NCT07600762 is a Phase 1 study that has not yet begun recruiting, run by AbbVie. The registered enrollment target is 12 participants.
The verdict
NCT07600762, a Phase 1 study, has not yet begun recruiting, sponsored by AbbVie.
- NOT YET RECRUITING
- Registry status
- Phase 1
- Development phase
- 12 participants
- Enrollment target
Study Summary
A Study to Assess Adverse Events, Tolerability and How a Single Oral Dose of Nacresertib Moves Through the Body In Healthy Adult Japanese Participants
Interventions
- DRUG Nacresertib
- DRUG Placebo for Nacresertib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2026-04-25 |
| Est. Completion | 2026-06 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07600762
The ClinicalTrials.gov registry entry for NCT07600762 describes a study currently listed as not yet recruiting, categorized as Phase 1. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AbbVie, which has 526 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Nacresertib is the first listed.
NCT07600762 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07600762 about?
NCT07600762 is a clinical study titled "A Study to Assess Adverse Events, Tolerability and How a Single Oral Dose of Nacresertib Moves Through the Body In Healthy Adult Japanese Participants". A Study to Assess Adverse Events, Tolerability and How a Single Oral Dose of Nacresertib Moves Through the Body In Healthy Adult Japanese Participants
What is the current status of trial NCT07600762?
This trial is currently not yet recruiting. It is a Phase 1 study. The enrollment target is 12 participants. The study started on 2026-04-25. Estimated completion is 2026-06.
What interventions are being tested in trial NCT07600762?
The interventions under investigation include: Nacresertib (DRUG), Placebo for Nacresertib (DRUG).
Who is sponsoring clinical trial NCT07600762?
This trial is sponsored by AbbVie, which has 526 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.